ArticleMolecular cell2017
PTEN Regulates PI(3,4)P
Open access · hybridAbstract read
In one paragraph
Article in Molecular cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 180 citations in OpenAlex.
- miR-19b-3p is associated with a diametric response to resistance exercise in older adults and regulates skeletal muscle anabolism via PTEN inhibition.American journal of physiology. Cell physiology · 2021Trial
- Spatiotemporal and quantitative analyses of phosphoinositides - fluorescent probe-and mass spectrometry-based approaches.FEBS letters · 2026Review
- PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Cancer research · 2026Article
- PIK3CA mutations and PI3K isoform expression define prognostic signatures in ovarian clear cell carcinoma.Archives of gynecology and obstetrics · 2026Article
- The proximal lipid phase of PI3K signaling is confined to the plasma membrane.bioRxiv : the preprint server for biology · 2026Article
- Approaches to visualize, quantify, and manipulate phosphoinositides in cells.Histochemistry and cell biology · 2026Review
- Targeting the Ras-Ral Signaling Axis in Type 2 Diabetes Mellitus: A Dual-Modulation Approach to Correcting Insulin Resistance and β-Cell Dysfunction.Pharmaceuticals (Basel, Switzerland) · 2026Review
- PIKI-1, a class II PI 3-kinase, functions in endocytic trafficking.PLoS genetics · 2026Article
- Targeted phytotherapy: essential oils, multi-target cancer action & nanodelivery.Frontiers in oncology · 2026Review
- Understanding Behavior of Biological Networks with Invariant Computation.Advances in experimental medicine and biology · 2026Article
- Non-redundant roles of the phosphoinositide phosphatases PTEN and PIPP in PI3K/AKT signaling in breast cancer.Communications biology · 2025Article
- Immunotherapy and targeted therapy for high grade gliomas: current and future directions.Journal of neuro-oncology · 2025Review
- Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.The Journal of clinical investigation · 2025Article
- Drivers of Pancreatic Cancer: Beyond the Big 4.Cancers · 2025Review
- AKT and DUBs: a bidirectional relationship.Cellular & molecular biology letters · 2025Review
- Optogenetic storage and release of protein and mRNA in live cells and animals.Nature communications · 2025Article
- mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.Orphanet journal of rare diseases · 2025Review
- PIKI-1, a class II phosphatidylinositol 3-kinase, functions in endocytic trafficking.bioRxiv : the preprint server for biology · 2025Article
- Lysosomal PIPProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Resveratrol aggravated H2O2-induced the HK-2 cell damage by inhibiting AKT phosphorylation.PloS one · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 6 institutions in 3 countries.
Mouhannad MalekSignalling Programme, Babraham Institute, Cambridge, UK.
Anna KielkowskaSignalling Programme, Babraham Institute, Cambridge, UK.
Tamara ChessaSignalling Programme, Babraham Institute, Cambridge, UK.
Karen E AndersonSignalling Programme, Babraham Institute, Cambridge, UK.
David BarnedaSignalling Programme, Babraham Institute, Cambridge, UK; AstraZeneca R&D Cambridge, CRUK Cambridge Institute, Cambridge, UK.
Pınar PirSignalling Programme, Babraham Institute, Cambridge, UK.
Hiroki NakanishiDepartment of Medical Biology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Japan.
Satoshi EguchiDepartment of Medical Biology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Japan.
Atsushi KoizumiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Japan.
Junko SasakiDepartment of Medical Biology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Japan.
Véronique JuvinSignalling Programme, Babraham Institute, Cambridge, UK.
Vladimir Y KiselevSignalling Programme, Babraham Institute, Cambridge, UK.
Izabella NiewczasSignalling Programme, Babraham Institute, Cambridge, UK.
Alexander GraySchool of Life Sciences, University of Dundee, Dow St., Dundee, UK.
Alexandre ValayerSignalling Programme, Babraham Institute, Cambridge, UK.
Dominik SpensbergerSignalling Programme, Babraham Institute, Cambridge, UK.
Marine ImbertSignalling Programme, Babraham Institute, Cambridge, UK.
Sergio FelisbinoDepartment of Morphology, Institute of Biosciences of Botucatu, Sao Paulo State University - UNESP, Botucatu, Sao Paulo, Brazil.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Japan.
Soren BeinkeRefractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
Sabina CosulichAstraZeneca R&D Cambridge, CRUK Cambridge Institute, Cambridge, UK.
Nicolas Le NovèreSignalling Programme, Babraham Institute, Cambridge, UK.
Takehiko SasakiDepartment of Medical Biology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Japan.
Jonathan ClarkSignalling Programme, Babraham Institute, Cambridge, UK.
Phillip T HawkinsSignalling Programme, Babraham Institute, Cambridge, UK. Electronic address: phillip.hawkins@babraham.ac.uk.
Len R StephensSignalling Programme, Babraham Institute, Cambridge, UK. Electronic address: len.stephens@babraham.ac.uk.
Babraham Institute · GBAkita University · JPAstraZeneca (United Kingdom) · GBGlaxoSmithKline (United Kingdom) · GBUniversidade Estadual Paulista (Unesp) · BRUniversity of Dundee · GB
Funding
Biotechnology and Biological Sciences Research Council BBS/E/B/0000H235Biotechnology and Biological Sciences Research Council BBS/E/B/000C0413Biotechnology and Biological Sciences Research Council BBS/E/B/000C0415Biotechnology and Biological Sciences Research Council BBS/E/B/000C0419Wellcome Trust
Abstract
The PI3K signaling pathway regulates cell growth and movement and is heavily mutated in cancer. Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P
Indexed as
Second Messenger SystemsAnimalsBreast NeoplasmsCell Line, TumorClass I Phosphatidylinositol 3-KinasesEpidermal Growth FactorFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansMaleMice, Inbred C57BLMice, KnockoutMutationPhenotypeClass I Phosphatidylinositol 3-KinasesEpidermal Growth Factorphosphatidylinositol-3,4-bisphosphate 4-phosphatasePhosphatidylinositolsphosphoinositide-3,4-bisphosphatePhosphoric Monoester HydrolasesPTEN PhosphohydrolasePTEN protein, humanPten protein, mousecancerINPP4BinvadopodiaPI(3,4,5)P(3)PI(3,4)P(2)PI3KprostatePTENSHIP2
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.